Thursday, October 15, 2026

Palantir and CrowdStrike Deploy NVIDIA's Long-Running AI Agents in Production

Palantir and CrowdStrike have adopted NVIDIA Nemotron to power persistent, long-running AI agents in enterprise environments. The move signals a transition from one-shot AI inference to autonomous, ongoing agents embedded in financial analytics and security workflows. Palantir's AIP platform serves hedge funds, banks, and government institutions.

LM Salvado
LM Salvado

June 7, 2026

Palantir and CrowdStrike Deploy NVIDIA's Long-Running AI Agents in Production
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Palantir and CrowdStrike are running NVIDIA Nemotron-powered AI agents in production — not as experimental tools, but as persistent autonomous systems embedded in live operations.1

The deployment marks a shift in how enterprise AI is consumed. Earlier AI integrations produced single responses to queries. Long-running agents instead monitor, reason, and act continuously across financial and security data streams.1

Palantir's AIP platform already anchors analytics infrastructure for hedge funds, investment banks, and government agencies.1 Adding autonomous agent capabilities positions the platform to handle tasks that previously required constant human oversight — portfolio surveillance, anomaly flagging, and compliance monitoring among them.

CrowdStrike's parallel adoption signals that financial institutions and security-sensitive enterprises are moving in step. Fraud detection and threat response both benefit from agents that operate continuously rather than on demand.1

The timing matters for investors watching Palantir's revenue trajectory. Agent capabilities are expected to feature in Q2 or Q3 2026 earnings as a new growth driver, with potential upward revisions to guidance.1 That framing shifts Palantir's story from data analytics vendor to autonomous operations infrastructure — a higher-value category.

For financial services specifically, the demand signal is clear. AI-augmented compliance and fraud detection have moved from pilot programs to production requirements.1 Regulators are increasing scrutiny; institutions need systems that document decisions and flag exceptions in real time, not after the fact.

NVIDIA's Nemotron models are optimized for agentic workloads — tasks requiring multi-step reasoning and sustained context. Their integration into Palantir's stack suggests the infrastructure layer for autonomous financial operations is already built. Deployment is the constraint, not capability.1

Hedge funds and banks evaluating AI infrastructure should watch how Palantir's AIP evolves over the next two quarters. The shift from analytics to autonomous agents changes the procurement calculus: instead of a reporting tool, it becomes an operational dependency.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com